ReviewFrontiers in pharmacology2026
Management of depression utilizing Traditional Chinese Medicine.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ethnobotanical Uses and Phytochemical, Pharmacological, Behavioral, and Toxicological Effects ofMolecules (Basel, Switzerland) · 2026Review
- Echinocystic Acid Antagonizes Post-Stroke Depression in Mice by Suppressing the JNK/NF-κB Signaling Pathway.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a major global health concern, characterized by profound mental and physical debilitation that severely impairs quality of life. The World Health Organization projects that it will become the second-leading cause of global disease burden by 2030, underscoring the urgent need for effective therapeutic strategies. However, the pathogenesis of depression remains incompletely elucidated, and first-line pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), are frequently limited by delayed clinical onset, suboptimal response rates, and notable adverse effects. In contrast, traditional Chinese medicine (TCM), with its holistic philosophy and potential for multi-target modulation, offers a promising complementary approach. This review systematically synthesizes contemporary research on TCM for depression, covering botanical drug formulas, single medicinal botanical drugs, and their purified bioactive metabolites. We critically evaluate the proposed mechanisms-spanning monoaminergic regulation, modulation of neurotrophic factors, anti-inflammatory activity, and interactions between the microbiota-gut-brain axis-and discuss the associated translational challenges and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.